FNY Investment Advisers LLC Takes $132,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

FNY Investment Advisers LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the first quarter, HoldingsChannel.com reports. The fund bought 4,500 shares of the company’s stock, valued at approximately $132,000.

Several other hedge funds have also bought and sold shares of HIMS. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the period. UMB Bank n.a. raised its stake in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after acquiring an additional 933 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the last quarter. Fifth Third Bancorp boosted its position in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock worth $46,000 after purchasing an additional 961 shares during the period. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at $38,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HIMS. Piper Sandler restated a “neutral” rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Needham & Company LLC boosted their price objective on Hims & Hers Health from $61.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, June 4th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Finally, TD Cowen lowered Hims & Hers Health from a “buy” rating to a “hold” rating and decreased their price objective for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $38.00.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $59.86 on Tuesday. The business has a fifty day moving average price of $45.77 and a two-hundred day moving average price of $38.46. The stock has a market capitalization of $13.40 billion, a PE ratio of 136.04 and a beta of 2.09. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the previous year, the firm earned $0.05 earnings per share. Hims & Hers Health’s revenue for the quarter was up 110.7% compared to the same quarter last year. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, COO Melissa Baird sold 33,333 shares of the firm’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the sale, the chief operating officer now owns 805,083 shares of the company’s stock, valued at approximately $20,755,039.74. This trade represents a 3.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 3,236 shares of the business’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $27.77, for a total value of $89,863.72. Following the transaction, the insider now directly owns 170,285 shares of the company’s stock, valued at $4,728,814.45. This trade represents a 1.86% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 476,653 shares of company stock worth $20,679,956. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.